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Retinitis pigmentosa (RP) is the most genetically and phe-
notypically heterogeneous disorder, characterized by the
progressive death of photoreceptor cells. In recent years,
huge advances have been made in understanding the dis-
ease mechanisms, identifying causal genes, and developing
therapeutic strategies for this disorder. This special issue
updates the knowledge of RP and presents original clinical
and experimental research.
Photoreceptor cell death is known to be characterized
at the early stage by caspase dependent or independent
apoptosis and at late stage by necrosis, but the molecular
mechanisms are not fully understood. In this special issue, S.
R. Patnaik et al. review the functional role of RPGR protein
complex in the pathogenesis of RP. Disease mechanisms are
further elucidated in mouse (Q. Zheng et al.) and zebrafish
models (Y. Liu et al. and S. Akhtar et al.). R. Migliorini et
al. discuss RP associated syndromes, such as impaired ocular
motility. E. Strobbe et al. report a correlation between ocular
inflammation and endothelin (ET-1) plasma levels in early RP
patients and suggest that anti-inflammatory therapymay slow
the progression of RP.
With the development of new technologies such as next
generation sequencing (NGS), more and more mutant genes
that cause retinal degenerative diseases have been found.
B. Gong et al. reported here a recessive RDH12 mutation
identified by exome sequencing in severe early onset RP
patients, which further verifies the application of NGS for
molecular diagnosis of RP.Meanwhile, many naturally occur-
ring or genetically engineered animal models have shown
gene mutations and phenotypes similar to human inherited
retinal diseases, which has led to the development of a variety
of therapeutic strategies for those inherited diseases regarded
traditionally as incurable.
Following the success of Leber congenital amaurosis 2
(LCA2) gene therapy clinical trials, more and more vector
based gene therapy clinical trials have been performed on
a variety of retinal conditions including RP with MERTK
mutation. AAV-mediated gene replacement therapy shows
great potential to treat patients in the early stage of the
disease. Gene replacement therapy combined with other ap-
proaches like treatment with histone deacetylases inhibitors
(reviewed by H. Zhang et al.) or antiapoptotic/inflammatory
chemicals or natural products, which can extend the thera-
peutic window in middle to late stages of those patients, is a
potentially promising strategy for improving photoreceptor
function and significantly slowing the process of retinal
degeneration. Cell replacement is a promising therapeutic
strategy for RP. Successful cell replacement treatments have
been done in RP animal models, providing hope for RP
patients and their families. Chinese medicine has a long
history in the treatment of RP; combinational treatment of
ChinesemedicinewithWesternmedicinemay further reduce
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